Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sanofi-aventis has reported that the anticoagulant Clexane has been approved for marketing in Japan by the Ministry of Health, Labour and Welfare, for the prevention of venous thromboembolism in patients undergoing orthopaedic surgery of the lower limbs such as total hip replacement, total knee replacement and hip fracture surgery.
Subscribe to our email newsletter
Clexane is used to inhibit clot formation in venous and arterial vessels to prevent potential acute or chronic complications of venous or arterial thrombosis. The recommended dose regimen of Clexane in Japan is 20mg b.I.d subcutaneous and has been established with the results of Japanese clinical trials.
Hanspeter Spek, executive vice president, pharmaceutical operations of Sanofi-aventis, said: “Clexane’s approval illustrates the commitment of sanofi-aventis to bring new life saving drugs to patients in Japan, where further clinical trials are being conducted with Clexane to extend its use to abdominal surgery patients who are at risk for venous thromboembolic complications.”